Physician profile
David J Tipton
NPI 1811915051
$4,310.68
in general payments reported to CMS, 2019-2025
45 companies · $17.99 in 2025
The $17.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $1,242 · 2021: $1,317 · 2022: $403 · 2025: $17.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $458.88 | 2019-2022 | |
| Amgen INC. | $343.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $343.87 | 2019-2021 | |
| Novo Nordisk INC | $321.11 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $316.89 | 2019-2022 | |
| Abbvie INC. | $312.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.91 | 2019-2022 | |
| Pfizer INC. | $191.66 | 2019-2021 | |
| Allergan, INC. | $187.19 | 2019-2020 | |
| Mylan Specialty L.P. | $181.46 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $126.65 | 2019-2021 | |
| Astellas Pharma US INC | $122.50 | 2019-2022 | |
| Amarin Pharma, INC. | $100.64 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $73.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $72.00 | 2020-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tipton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.